This activity is supported by an educational grant from Amgen.
NPs and PAs specializing in rheumatology
Describe key points from the American College of Rheumatology (ACR) 2021 RA guidelines
Utilize the latest data and recommendations for switching patients to another DMARDâor combination of DMARDsâif the current approach fails or leads to an inadequate response
Select patients who are the most appropriate candidates for Janus kinase inhibitor therapy and follow them for adverse events according to the latest data and guidelines
All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Robin Dore, MD: consultant/advisor/speaker fees: AbbVie, Amgen, Janssen, Lilly, Pfizer, Sanofi, UCB.
Shannon Ghizzoni, PA-C: consultant/advisor/speaker: AbbVie, Amgen, Novartis.
Benjamin J. Smith, DMSc, PA-C, has no relevant financial relationships to disclose.
Jennifer Simpson, DNP: consultant/advisor/speaker: Abbvie, Amgen, AstraZeneca, Horizon, Janssen.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose except Jennifer Simpson, DNP as noted above.
Learners wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.00 hour.
Release date: October 10, 2022
Expiration date: October 9, 2023
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange, Partners for Advancing Clinical Education, or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Jennifer Simpson, DNP, Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 9, 2023. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program has been made available online.